The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System DOI
Jianxing Zhou, Zipeng Wei,

Weipeng Lai

et al.

British Journal of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 10, 2024

The use of (GLP-1 RAs) among pregnant women is escalating, yet safety data remain insufficient. This study aims to comprehensively assess adverse drug reactions (ADRs) associated with GLP-1 RAs in using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Language: Английский

Data mining study on adverse events of tirzepatide based on FAERS database DOI

Yan Huo,

Minghua Ma, Xiaolan Liao

et al.

Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 9

Published: July 15, 2024

Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes or obesity. To explore the safety profile of tirzepatide in real-world clinical applications.

Language: Английский

Citations

1
Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System DOI
Jianxing Zhou, Zipeng Wei, Wei Huang

et al.

Annals of Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 20, 2024

Alzheimer's disease (AD) is a neurodegenerative condition leading to memory loss, cognitive impairment, and neuropsychiatric symptoms. Second-generation antipsychotics (SGAs) are commonly used manage these symptoms, but their safety profile in patients with AD requires further investigation.

Language: Английский

Citations

1
Exploration of the Potential Association between Newer Antiseizure Medications and Arrhythmias: Integrating Pharmacovigilance and Bioinformatics Evidence DOI
Jianxing Zhou,

Zhenhui Chen,

Mengjun Zhang

et al.

Seizure, Journal Year: 2024, Volume and Issue: 123, P. 26 - 33

Published: Oct. 17, 2024

Language: Английский

Citations

1
Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system DOI

Haoquan Huang,

Chuwen Hu,

Fan Liu

et al.

British Journal of Anaesthesia, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Language: Английский

Citations

1
The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System DOI
Jianxing Zhou, Zipeng Wei,

Weipeng Lai

et al.

British Journal of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 10, 2024

The use of (GLP-1 RAs) among pregnant women is escalating, yet safety data remain insufficient. This study aims to comprehensively assess adverse drug reactions (ADRs) associated with GLP-1 RAs in using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Language: Английский

Citations

1